Risk Partners Life Sciences Roundtable 2024, thank you very much! Sign up now for the 26.06.2025 >

Contact us

๐—š๐—น๐—ผ๐—ฏ๐—ฎ๐—น ๐—œ๐—ป๐˜๐—ฒ๐—ด๐—ฟ๐—ถ๐˜๐˜† ๐—ฎ๐—ป๐—ฑ ๐—–๐—ผ๐—บ๐—ฝ๐—น๐—ถ๐—ฎ๐—ป๐—ฐ๐—ฒ ๐—™๐—ผ๐—ฟ๐˜‚๐—บ ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฐ

"D&O and Co. - Plan B to cover personal liability!"

Last Friday, Florian had the honor of attending the Global Integrity and Compliance Forum at the Ludwig-Maximilians-Universitรคt in Munich. Under the motto "The RULE of LAW in the Era of Integrity & Compliance", international legal experts, company managers, in-house councils and compliance officers from all over the world gathered to discuss the future of good corporate governance in 2024.

Key discussions and findings One of the main topics was the liability of company directors and members of the supervisory board, which underlined the increasing importance of a comprehensive risk management strategy. It became clear that an effective compliance management system is not only necessary today, but must also be documented and comprehensible. Florian led an important session on "D&O and Co. - Plan B to cover personal liability", in which he showed how board members can protect themselves from liability through personal risk management. Here are some of the key points:

1. contractual agreements:
  • Indemnification and procurement clauses in the secondment or mandate agreement
  • Overview and assurances from the company's D&O insurance

2. tool-based approaches:
  • Use of corporate governance tools, such as Fides
  • Compliance with the Business Judgement Rule and documentation of concerns of the Supervisory Board to mitigate personal liability

3. D&O protection:
  • Regular due diligence of the corporate D&O
  • Examination of supplementary private provision (personal D&O, top manager legal protection, etc.)

Thanks and outlook

Special thanks to Alexander Schemmel, the Boston Consulting Group (BCG) and the GCE Counsellors at Law team for the invitation and the opportunity to participate in this inspiring event. The exchange with the experts and the discussions in the LMU premises were extremely enriching.

Are you a member of the executive board, managing director or supervisory board yourself? Let's discuss, without obligation, how our special concepts of software solutions and D&O insurance can protect you and offer best practices for personal protection in a modern management environment. Together we can further improve corporate governance and ensure greater integrity and compliance in the business world. We look forward to hearing from you!

Also read our other blog posts

Being Public

Whistleblower Protection Act

Whistleblower Protection Act ... is now in force. Hey #VCs, do you already have a system in place for safe #whistleblowing? And what about insurance cover in your D&O insurance? One month ago today, the German Whistleblower Protection Act came into force. Since July 2, 2023, not only companies with more than 50 employees, but also fund managers or ManCos (capital management companies pursuant to Section 17 (1) of the German Investment Code) are obliged to set up and operate a whistleblower system, regardless (!) of the number of employees. As of December 2

Read more "
October 31, 2023
Being Public

Risk Partners supports successful uplisting of Formycon AG to the Prime Standard

Congratulations to Formycon AG on its successful uplisting to the Prime Standard of Deutsche Bรถrse on November 12, 2024! Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the Scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the field of biosimilars! Formycon AG has focused on

Read more "
November 14, 2024
Risk Partners

13th Hamburg Financial Lines Forum

Risk Partners at the Financial Lines Forum 13th Hamburg Financial Lines Forum. On October 12 and 13, 2023, the 13th Hamburg Financial Lines Forum took place with the participation of Risk Partners, a traditional event that once again served as a platform for the exchange of current trends. The program began with an overview of current developments and the handling of claims in financial lines, presented by Gabriele Schreiber-Sahin and Michael Hendricks. Dr. Oliver Sieg then shed light on directors' and officers' liability and the

Read more "
October 28, 2023
Life Sciences

Cyber Risks: Case Study Evotec

Last year, more than 10 percent of German companies were affected by an IT security incident, with the proportion rising due to cyber attacks. Biotechnology is not excluded either. It is possible to learn from the Evotec case. It is about successful cyber attacks or other incidents that are important for security, such as acts of sabotage or hardware theft. According to a representative Ipsos survey conducted on behalf of the TรœV association among 501 companies with more than ten employees. According to the TรœV

Read more "
October 22, 2023
Being Public

Revolution in D&O insurance in Nevada (US insurance market) postponed

The revolution in D&O insurance in Nevada has been called off after all. In the US market, the state of Nevada passed an interesting law (Bill No. 398) in the summer with potentially significant implications for the D&O insurance market. The Governor of Nevada approved the bill on June 3, 2023, so the law came into force on October 1, 2023. We had classified this legislation (in the USA, insurance supervision is organized at state level) as too watchful for our clients, but this law

Read more "
December 9, 2023
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
September 26, 2023